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Endothelin receptor antagonism has emerged as an important therapeutic strategy in
pulmonary arterial hypertension (PAH). Laboratory and clinical investigations have clearly
shown that endothelin (ET)-1 is overexpressed in several forms of pulmonary vascular disease
and likely plays a significant pathogenetic role in the development and progression of
pulmonary vasculopathy. Oral endothelin receptor antagonists (ERAs) have been shown to
improve pulmonary hemodynamics, exercise capacity, functional status, and clinical outcome
in several randomized placebo-controlled trials. Bosentan, a dual-receptor antagonist, is
approved by the U.S. Food and Drug Administration for class III and IV patients with PAH,
based on two phase III trials. In addition to its efficacy as sole therapy, bosentan may have a
role as part of a combination of drugs such as a prostanoid or sildenafil. The selective
endothelin receptor-A antagonists sitaxsentan and ambrisentan are currently undergoing
investigation. (J Am Coll Cardiol 2004;43:62S–67S) © 2004 by the American College of
Cardiology Foundationa
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cince the last World Symposium on Pulmonary Hyperten-
ion in Evian, France, in 1998, endothelin receptor antag-
nism has emerged as a cornerstone of therapy for pulmo-
ary arterial hypertension (PAH). Elucidation of the role of
ndothelin in the pathogenesis and progression of pulmo-
ary vascular disease, the efficacy of endothelin receptor
ntagonists (ERAs) in randomized clinical trials, and long-
erm outcome data have placed this therapy at the forefront
f the treatment armamentarium. We review here the
urrent state of knowledge related to ERAs in the context of
he treatment algorithm described elsewhere in this supple-
ent.
NDOTHELIN (ET)-1 AS AN
MPORTANT MEDIATOR IN PAH
he endothelins are a family of 21 amino-acid peptides that
lay a key role in the regulation of vascular tone. The first
ember of this family identified was ET-1, a 2492-dalton
Da) peptide with potent vasoconstrictor properties, isolated
y Yanagisawa et al. in 1988 (1). Two additional endothelin
sopeptides—ET-2 and ET-3—were subsequently discov-
red. The ET-1 appears to play the most prominent role in
ascular control. Knowledge of the mechanisms and molec-
lar aspects of ET-1 is important in understanding the
herapeutic value of endothelin receptor antagonism.
RODUCTION OF ET-1
he majority of ET-1 secreted from cultured endothelial
ells occurs from the abluminal side of the cells toward the
From the *Pulmonary and Critical Care Division, University of California, San
iego, California; †Division of Pulmonary and Critical Care Medicine, University of
aris-Sud, Paris, France; ‡Division of Pediatric Cardiology, Columbia–Presbyterian
ospital, New York, New York; §Institute of Cardiology, University of Bologna,
ologna, Italy.vManuscript received January 13, 2004; accepted February 3, 2004.djacent vascular smooth muscle cells, which contain spe-
ific endothelin receptors (2). Thus, it is important to note
hat, although circulating ET-1 can be detected in the
lasma and may have important clinical correlations with
ulmonary vascular disease, these plasma levels may not
ecessarily reflect the paracrine action of ET-1 on adjacent
mooth muscle cells.
NDOTHELIN RECEPTORS
here are two distinct receptors for the endothelin family of
eptides, endothelin receptor A (ETA) and endothelin
eceptor B (ETB). The endothelin receptors belong to the
amily of receptors connected to guanine nucleotide-binding
G) proteins (3). The two receptors have unique locations
4) and binding affinities (5) for the endothelin peptides.
he ETA receptors are expressed on pulmonary vascular
mooth muscle cells, whereas ETB receptors are located on
oth pulmonary vascular endothelial cells and smooth mus-
le cells.
When activated, the ETA receptor located in pulmonary
ascular smooth muscle cells mediates a potent vasocon-
trictive response, thought to occur via G-protein–induced
hospholipase C activation: 1,4,5-inositol triphosphate for-
ation with the consequent release of Ca2 from intracel-
ular stores (3). There is also evidence that the ETA receptor
ediates increased intracellular calcium by activating non-
elective calcium channels on the surface of the smooth
uscle cell (6). The vasoconstriction induced by ETA has
een shown to persist even after ET-1 is removed from the
eceptor, likely due to persistently elevated concentrations of
ntracellular Ca2 (7).
In addition to its powerful vasoconstricting effects, ET-1
s known to be a potent mitogen, with the ability to induce
ell proliferation in a number of cell types, including
ascular smooth muscle cells (8). It has been shown that the
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June 16, 2004:62S–67S Endothelin Receptor Antagonists in PAHitogenic actions of ET-1 are mediated by both the ETA
9) and ETB (10) receptors.
In the normal pulmonary vasculature, ETB receptors are
redominantly expressed on endothelial cells (11,12). The
TB receptors on endothelial cells mediate vasodilation via
ncreased production of nitric oxide and prostacyclin (12–
4). Nitric oxide and prostacyclin also negatively feed back
n ET-1 activity by inhibition of preproendothelin-1 tran-
cription. In addition, ET-1 is cleared by ETB receptors.
Data suggest that the ETB receptor does not exclusively
ediate pulmonary vasodilation. Under some circumstances
t may actually contribute to pulmonary vasoconstriction,
hrough a population of ETB receptors located on vascular
mooth muscle cells (15). The vasoconstrictive actions of
he ETB receptor may become more pronounced in the
athologic setting of pulmonary hypertension (16), possibly
ue to upregulation of ETB receptors in states of pulmonary
ypertension (17). The functions of both receptors under
athologic conditions may therefore determine whether
ntagonizing one or both receptors is preferable.
In patients with PAH, several derangements in ET-1
xpression and activity have been demonstrated. Patients
ith idiopathic pulmonary arterial hypertension (IPAH,
ormerly called primary pulmonary hypertension) have been
hown to have higher serum levels of ET-1 and higher
rterial-to-venous ratios of ET-1 than do healthy controls
18). Endothelin levels have also been shown to correlate
ith pulmonary hemodynamics (19). In addition, lung
pecimens from patients with IPAH (formerly primary
ulmonary hypertension), when compared to those from
atients without pulmonary hypertension, exhibit increased
T-1 staining of the muscular pulmonary arteries (20).
lso, PAH associated with congenital cardiac disease has
een shown in human investigations to correlate with high
evels of ETA receptor density and circulating ET-1, which
n some instances decrease following surgical correction of
he cardiac lesions (21–23).
Chronic thromboembolic pulmonary hypertension
CTEPH) has also been associated with increased activity of
he ET-1 system in both animal (24,25) and human (26)
athologic studies. Pulmonary hypertensive changes were
ttenuated in the presence of combined ETA/ETB receptor
Abbreviations and Acronyms
CTEPH  chronic thromboembolic pulmonary
hypertension
ERAs  endothelin receptor antagonists
ET  endothelin
ETA  endothelin receptor A
ETB  endothelin receptor B
IPAH  idiopathic pulmonary arterial hypertension
6MWT  6-min walk test
PAH  pulmonary arterial hypertension
WHO  World Health Organization
NYHA  New York Heart Associationlockade in a canine model of CTEPH (24). It is known bhat many patients with CTEPH have a concomitant small
essel vasculopathy that can limit the hemodynamic im-
rovement following pulmonary thromboendarterectomy,
uggesting a pathogenetic role for endothelin in this process.
LINICAL USE OF ERAs
iven the prominent role that ET-1 appears to play in
everal forms of pulmonary hypertension, ERAs have a
trong rationale. There is now one approved ERA, oral
osentan, for the treatment of PAH. Other ERAs are
urrently under investigation.
osentan. Bosentan is an antagonist of both the ETA and
TB receptors, with only slightly higher in vitro affinity for
he ETA receptor. Two randomized clinical trials led to U.S.
ood and Drug Administration (FDA) approval of bosen-
an for PAH patients who are functional class III or IV.
The first multicenter randomized placebo-controlled
tudy of chronic oral bosentan was performed by Channick
nd colleagues in 32 patients with IPAH (n  27) or with
AH related to scleroderma (n  5) (27). Recruited
atients were all World Health Organization (WHO)
unctional class III, and there was 2:1 randomization to the
osentan group in relation to placebo. Patients in the
osentan group received the drug at a dose of 62.5 mg twice
aily for four weeks followed by 125 mg twice daily.
oncurrent therapy with digoxin, anticoagulants, diuretics,
nd calcium channel blockers was permitted; however,
atients receiving epoprostenol were excluded. The primary
nd point was exercise capacity as measured by the 6-min
alk test (6MWT) and secondary end points included
emodynamic improvement by right heart catheterization,
hange in functional class, and time to clinical worsening—
ll measured at 12 weeks. The intention-to-treat analysis
emonstrated statistically significant improvements in the
osentan group compared to placebo in 6MWT, with a
ean treatment effect of 76 m and pulmonary hemodynam-
cs (cardiac output, pulmonary vascular resistance, mean
ulmonary arterial pressure) (Fig. 1).
A subsequent larger double-blind, placebo-controlled
tudy of bosentan in PAH by Rubin et al. (28) enrolled 213
atients with IPAH (n  150) or PAH related to sclero-
erma (n  47) or systemic lupus erythematosus (n  16).
ll patients belonged to WHO functional class III or IV.
aseline parameters included mean 6MWT of 330 m,
nd mean pulmonary artery pressures of 55 mm Hg.
atients randomized to the bosentan group received 62.5
g twice daily for four weeks, then either 125 mg twice
aily (n  74) or 250 mg twice daily (n  70) for an
dditional 12 weeks, in comparison to placebo (n  69).
he primary end point was functional status as measured by
he 6MWT at 16 weeks. This trial also showed a statistically
ignificant improvement in 6MWT in both bosentan
roups in comparison to placebo (Fig. 2). Analysis of
econdary measures of efficacy revealed a trend in the
osentan groups toward lower Borg dyspnea indices and
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Endothelin Receptor Antagonists in PAH June 16, 2004:62S–67Smproved functional class. There was also a statistically
ignificant increase in the bosentan groups in time to clinical
orsening (Fig. 3), as measured by the composite end point
f time to death, lung transplantation, hospitalization, or
tudy dropout because of worsening pulmonary hyperten-
ion, need for epoprostenol therapy, or atrial septostomy. In
ddition, in a subgroup of 85 patients enrolled in an
chocardiographic substudy, bosentan improved different
chocardiographic and Doppler parameters related to the
ight ventricular systolic function and the left ventricular
arly diastolic filling (29).
Data on the long-term efficacy of bosentan are now
vailable. A recent report by Sitbon et al. (30) demonstrated
ustained improvement in functional class and pulmonary
emodynamics for at least one year.
Mortality data for 169 patients treated with bosentan as
rst-line therapy was recently presented by McLaughlin et
l. (31). In that report, three-year survival was 86% com-
ared to a predicted survival of 48% for these individuals
ased on a validated National Institutes of Health (NIH)
urvival equation. In this cohort, at two years, 70% of
atients were still maintained on bosentan alone.
igure 1. Hemodynamic effects of bosentan versus placebo at 12 weeks.
PVR), and mean pulmonary arterial pressure (mPAP) were all noted. The
l. (27)—original work. Control group is shown in blue; bosentan group is
ersus baseline.
igure 2. Six-minute walk distance improvement seen in study of 213
atients demonstrating significant treatment effect of bosentan. (From
ubin et al. [28]).afety. Bosentan is primarily eliminated by hepatic metab-
lism through the P450 enzyme systems CYP2C9 and
YP3A4. Steady-state levels are usually achieved after three
o five days with twice daily dosing. Upon reaching steady-
tate, the elimination half-life becomes constant. One me-
abolite of bosentan (Ro 48-5033) is pharmacologically
ctive but is believed to contribute 20% of the clinical
esponse to bosentan. Renal clearance of bosentan appears
o be negligible.
Clinical evidence suggests that bosentan administration
an precipitate hepatocellular injury, particularly at higher
oses. Combined data from existing clinical trials reveal
reater than threefold elevations of the aminotransferases in
1% of bosentan patients (n  658) compared with 2% of
atients given placebo (n  280). This effect was observed
oth early and late in treatment. The more severe elevations
n aminotransferases were observed in the patients receiving
50 mg twice daily or higher. The liver abnormalities were
ften asymptomatic and all resolved with dose reduction or
essation. In some patients, reintroduction of bosentan did
ot lead to recurrent hepatic enzyme elevations. Studies in
ats have revealed that bosentan-induced liver injury is likely
ediated by drug-induced inhibition of the hepatocanalicu-
ar bile-salt export pump (32).
Patients on bosentan must undergo monitoring of the
lanine aminotransferase and aspartate aminotransferase
efore drug initiation and monthly thereafter. Patients with
ignificant baseline hepatic dysfunction should not be given
osentan. In patients with hepatic congestion from right
eart failure, aggressive diuresis may correct abnormal
minotransferases occurring solely on this basis, and conse-
uently requalify these patients for bosentan.
Bosentan is contraindicated in pregnancy. Animal models
eveal that the endothelin peptides appear to play an
mportant role in fetal development. In one study (33) ET-1
as implicated in the closure of the ductus arteriosus at
irth. Mice with ET-1 deficiency (34) and those given
cant improvements in cardiac index (CI), pulmonary vascular resistance
ebo group worsened over the 12-week period. Adapted from Channick et
n in green. ‡Significant improvement versus baseline; *Significant declineSignifi
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June 16, 2004:62S–67S Endothelin Receptor Antagonists in PAHosentan (product monograph, Actelion Pharmaceuticals,
llschwill, Switzerland) as fetuses develop severe craniofa-
ial abnormalities. Pregnancy must be excluded before
herapy with bosentan and prevented thereafter with reliable
ontraception. Hormonal forms of contraception may not
e reliable in the setting of bosentan therapy, and thus
hould not be the sole form of contraception in females of
hildbearing potential.
Other common side effects observed with bosentan in-
lude a dose-related decrease in hemoglobin of unknown
tiology, headaches, and flushing.
Several drugs have been shown to interact with bosentan
hrough the P450 system. Glyburide and cyclosporine A are
ontraindicated with concurrent bosentan therapy. Al-
hough a small study has shown that humans given bosentan
00 mg twice daily have reduced warfarin effect (35), no
nfluence on warfarin activity has been seen in the clinical
rials using the 125-mg and 250-mg twice-daily doses of
osentan.
ole in the context of existing treatments for PAH.
osentan received approval in 2001/2002 by a number of
egulatory agencies, including those in Canada and the U. S.
he approved indications are PAH, with functional class III
r IV. For WHO functional class III and possibly early class
V patients who are not acutely vasoreactive or who have
ailed calcium channel blocker therapy, bosentan should be
onsidered the initial treatment of choice, based on com-
elling short- and long-term data. For patients with signif-
cant hemodynamic decline, especially with signs of overt
ight ventricular failure, or those who progress to WHO
unctional class IV, epoprostenol remains the initial therapy
f choice. These recommendations are outlined elsewhere in
his supplement as part of a consensus treatment algorithm.
igure 3. Delay in clinical worsening in bosentan-treated patients. C
ospitalization for worsening pulmonary arterial hypertension, or initiatioThe addition of bosentan to epoprostenol is a potentially attractive approach, as the two agents work through differ-
nt and possibly complementary mechanisms. A random-
zed controlled trial of combined epoprostenol–bosentan
ound a trend toward greater percent reduction in total
ulmonary resistance with the combination versus repopro-
tenol alone (36).
ELECTIVE ETA ANTAGONISTS
elective antagonists of the ETA receptor are currently
ndergoing investigation, with the rationale that the “favor-
ble” actions of the ETB receptor will remain intact and
fficacy further improved. Sitaxsentan sodium, a potent
ndothelin receptor antagonist that has oral bioavailability
nd a long duration of action (t1/2, 5 to 7 h), is approxi-
ately 6,500-fold more selective as an antagonist for ETA
ompared with ETB receptors. In the first randomized,
ouble-blind, placebo-controlled trial with sitaxsentan in
AH, 178 New York Heart Association (NYHA) func-
ional class II, III, and IV patients with either PPH, PAH
elated to connective tissue disease, or PAH related to
ongenital systemic to pulmonary shunts were equally ran-
omized to receive placebo, sitaxsentan 100 mg, or sitax-
entan 300 mg, orally once daily (37). Although the primary
fficacy end point of maximum oxygen consumption was not
mproved by sitaxsentan compared to placebo, the drug did
mprove exercise capacity (6-min walk distance) (Fig. 4) and
unctional class after 12 weeks of treatment. These func-
ional benefits occurred with both the 100-mg and the
00-mg doses. Treatment effects in the sitaxsentan groups
ere 35 m (p  0.01) for the 100-mg dose and 33 m (p 
.01) for the 300-mg dose. The NYHA functional class
mproved in 16 of 55 (29%) patients in the 100-mg group
worsening was defined as death, premature withdrawal from study,
poprostenol. (From Rubin et al. [28]).linicalnd in 19 of 63 (30%) patients in the 300-mg group. In
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Endothelin Receptor Antagonists in PAH June 16, 2004:62S–67Sontrast, only 9 of 60 (15%) patients in the placebo group
ad improvement in NYHA functional class. Improvements
n pulmonary vascular resistance and cardiac index were also
oted in the sitaxsentan group.
As with bosentan, liver function abnormalities occurred
10% in the 300-mg group). It should be noted that, in an
arlier pilot study, sitaxsentan was associated with fatal hepa-
itis when used at higher doses (38). In the larger randomized
rial, the most frequently reported clinical adverse events with
itaxsentan treatment (and more frequent than in placebo)
ere headache, peripheral edema, nausea, nasal congestion,
nd dizziness, reactions previously noted with ET-receptor
ntagonists. The most frequently reported laboratory adverse
vent was increased international normalized ratio or pro-
hrombin time, related to the effect of sitaxsentan on inhibition
f CYP2C9 P450 enzyme, the principal hepatic enzyme
nvolved in the metabolism of warfarin. A second phase III trial
f sitaxsentan is currently underway.
Another ETA antagonist, ambrisentan, is currently in phase III
linical trials in patients with PAH, and information on relative
afety and efficacy will be forthcoming in the near future.
UTURE DIRECTIONS IN ERA THERAPY
ndothelin receptor antagonists for the therapy of PAH
ppear to have great promise. Questions that remain to be
nswered include 1) the role of ERAs in early PAH (i.e.,
HO class I and II); 2) ERAs as part of combination
herapy—for example, with epoprostenol, treprostinil, or
ildenafil; 3) the value of selective versus nonselective
ndothelin receptor antagonism; and 4) the role of ERAs in
reating other conditions such as CTEPH or fibrotic lung
isease.
eprint requests and correspondence: Dr. Richard N. Chan-
ick, UCSD Medical Center, 9300 Campus Point Drive, La Jolla,
alifornia 92037. E-mail: rchannick@ucsd.edu.
igure 4. Six-minute walk distance improvement seen in study of 178 pati
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